Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer

ObjectivesThe purpose of this study was to determine whether multiparametric magnetic resonance imaging (MRI) using dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DWI), obtained before and after the first cycle of neoadjuvant chemotherapy (NAC), is superior to single-parameter measurements for predicting pathologic complete response (pCR) in patients with breast cancer. Materials and MethodsPatients with stage II/III breast cancer were enrolled in an institutional review board–approved study in which 3-T DCE-MRI and DWI data were acquired before (n = 42) and after 1 cycle (n = 36) of NAC. Estimates of the volume transfer rate (Ktrans), extravascular extracellular volume fraction (ve), blood plasma volume fraction (vp), and the efflux rate constant (kep = Ktrans/ve) were generated from the DCE-MRI data using the Extended Tofts-Kety model. The apparent diffusion coefficient (ADC) was estimated from the DWI data. The derived parameter kep/ADC was compared with single-parameter measurements for its ability to predict pCR after the first cycle of NAC. ResultsThe kep/ADC after the first cycle of NAC discriminated patients who went on to achieve a pCR (P < 0.001) and achieved a sensitivity, specificity, positive predictive value, and area under the receiver operator curve (AUC) of 0.92, 0.78, 0.69, and 0.88, respectively. These values were superior to the single parameters kep (AUC, 0.76) and ADC (AUC, 0.82). The AUCs between kep/ADC and kep were significantly different on the basis of the bootstrapped 95% confidence intervals (0.018–0.23), whereas the AUCs between kep/ADC and ADC trended toward significance (−0.11 to 0.24). ConclusionsThe multiparametric analysis of DCE-MRI and DWI was superior to the single-parameter measurements for predicting pCR after the first cycle of NAC.

[1]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[2]  E. L. Lehmann,et al.  Parametric versus nonparametrics: two alternative methodologies , 2009 .

[3]  K. Pinker,et al.  Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the “Breast Imaging Reporting and Data System” for multiparametric 3-T imaging of breast lesions , 2013, European Radiology.

[4]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[5]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.

[6]  Horst K. Hahn,et al.  Deformable Image Registration of Follow-Up Breast Magnetic Resonance Images , 2010, WBIR.

[7]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[9]  Xia Li,et al.  DCE‐MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings , 2014, Magnetic resonance in medicine.

[10]  T. Helbich,et al.  Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis? , 2009, Radiology.

[11]  T. Bathen,et al.  Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients , 2011, Journal of magnetic resonance imaging : JMRI.

[12]  Thomas E Yankeelov,et al.  Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy. , 2013, Translational oncology.

[13]  Thomas E Yankeelov,et al.  Temporal sampling requirements for reference region modeling of DCE‐MRI data in human breast cancer , 2009, Journal of magnetic resonance imaging : JMRI.

[14]  Carmel Hayes,et al.  Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.

[15]  Wolfgang Bogner,et al.  A Combined High Temporal and High Spatial Resolution 3 Tesla MR Imaging Protocol for the Assessment of Breast Lesions: Initial Results , 2009, Investigative radiology.

[16]  Ning-Yu An,et al.  Differentiation of clinically benign and malignant breast lesions using diffusion‐weighted imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[17]  S. Rodenhuis,et al.  Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[19]  Carsten Denkert,et al.  Response-guided neoadjuvant chemotherapy for breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jie Chen,et al.  Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? , 2012, Breast Cancer Research and Treatment.

[21]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[22]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[23]  Thomas E Yankeelov,et al.  Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. , 2013, Magnetic resonance imaging.

[24]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Thomas E Yankeelov,et al.  The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer. , 2011, Seminars in oncology.

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[27]  Thomas E Yankeelov,et al.  Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.

[28]  Olav Engebraaten,et al.  Low‐molecular contrast agent dynamic contrast‐enhanced (DCE)‐MRI and diffusion‐weighted (DW)‐MRI in early assessment of bevacizumab treatment in breast cancer xenografts , 2013, Journal of magnetic resonance imaging : JMRI.

[29]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[30]  F. Penault-Llorca,et al.  Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. , 2008, Human pathology.

[31]  Jung Hee Shin,et al.  Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy. , 2014, European journal of radiology.

[32]  Thomas E Yankeelov,et al.  A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer , 2011, Physics in medicine and biology.

[33]  Guy Marchal,et al.  Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.

[34]  Lorenzo Bonomo,et al.  Diffusion‐weighted Imaging in Evaluating the Response to Neoadjuvant Breast Cancer Treatment , 2011, The breast journal.

[35]  Andreas Makris,et al.  Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.

[36]  B. Tromberg,et al.  Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy , 2011, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[37]  Min-Ying Su,et al.  Monitoring the Size and Response of Locally Advanced Breast Cancers to Neoadjuvant Chemotherapy (Weekly Paclitaxel and Epirubicin) with Serial Enhanced MRI , 2003, Breast Cancer Research and Treatment.

[38]  Xia Li,et al.  Research and applications: Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy , 2013, J. Am. Medical Informatics Assoc..

[39]  S. Gautam,et al.  Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. , 2010, Radiology.

[40]  A. Taghian,et al.  Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application. , 2013, Archives of pathology & laboratory medicine.

[41]  Fernanda Philadelpho Arantes Pereira,et al.  Assessment of breast lesions with diffusion-weighted MRI: comparing the use of different b values. , 2009, AJR. American journal of roentgenology.

[42]  Wolfgang Bogner,et al.  Readout-segmented echo-planar imaging improves the diagnostic performance of diffusion-weighted MR breast examinations at 3.0 T. , 2012, Radiology.

[43]  E. Eisenhauer,et al.  RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.

[44]  K. Bland,et al.  Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. , 2011, Clinical breast cancer.

[45]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[46]  Xia Li,et al.  Statistical comparison of dynamic contrast‐enhanced MRI pharmacokinetic models in human breast cancer , 2012, Magnetic resonance in medicine.

[47]  Daniele Regge,et al.  Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging , 2004, Breast Cancer Research and Treatment.

[48]  A. Padhani,et al.  Multiparametric imaging of tumor response to therapy. , 2010, Radiology.

[49]  B. Naume,et al.  Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging , 2010, European Radiology.

[50]  L. Esserman,et al.  Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. , 2012, Radiology.

[51]  U. Sharma,et al.  Longitudinal study of the assessment by MRI and diffusion‐weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy , 2009, NMR in biomedicine.

[52]  Thomas E Yankeelov,et al.  Motion correction in diffusion‐weighted MRI of the breast at 3T , 2011, Journal of magnetic resonance imaging : JMRI.

[53]  Conspicuity of breast lesions at different b values on diffusion-weighted imaging , 2012, BMC Cancer.

[54]  N. Perkins,et al.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. , 2006, American journal of epidemiology.

[55]  Ming-Ting Wu,et al.  Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. , 2007, Academic radiology.

[56]  Oliver Geier,et al.  Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy , 2010, Acta oncologica.

[57]  Steinar Lundgren,et al.  Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE‐MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[58]  Guy Marchal,et al.  Multi-modality image registration by maximization of mutual information , 1996, Proceedings of the Workshop on Mathematical Methods in Biomedical Image Analysis.

[59]  T. Helbich,et al.  Improved Diagnostic Accuracy With Multiparametric Magnetic Resonance Imaging of the Breast Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Diffusion-Weighted Imaging, and 3-Dimensional Proton Magnetic Resonance Spectroscopic Imaging , 2014, Investigative radiology.